Clinical trial
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
NCT03933202
Study timeline
Study start (actual)2019-07-22Date precision: day
Registry last updated2026-01-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
Merck KGaA, Darmstadt, Germanycollaborator
Mapped research locations
RichmondVirginia, United States3TampaFlorida, United States2MilwaukeeWisconsin, United States2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1MiamiFlorida, United States1San AntonioTexas, United States1NashvilleTennessee, United States1CincinnatiOhio, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03933202 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.